Sequenom reports preliminary FY13 total revenue around $162M, consensus $165.45M The company announced preliminary 2013 performance results. The company sees total revenue of approximately $162M, showing growth of approximately 81% year-over-year for 2013. Diagnostic services revenues of approximately $120M, as compared to $46.5M in 2012. Diagnostic services revenues continue to be recorded primarily as cash is received. The company added that it sees high margin stable revenue in the Sequenom Bioscience business of over $42M. Total cash, cash equivalents and marketable securities as of December 31 were approximately $71M and cash burn was reduced to approximately $14M for Q413. Unrecorded diagnostic accounts receivable are estimated to be $46M to $51M as of December 31.